CD274 and neoplasm: Among tumor samples that were predicted to have a positive immune response to a single regimen of PD-1/PD-L1 (Fig. 8B) or CTLA4 inhibitors (Fig. 8C) and a positive immune response to both regimens (Fig. 8D), the ensemble average of IPS in the low-risk group were higher than those in the high-risk group, and the differences were statistically significant.